clinical trialJanssen Biotech has entered into a clinical study collaboration agreement with Bristol-Myers Squibb to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC).

The Phase II clinical trial will evaluate the tolerability and clinical activity of the combination of Janssen’s investigational immunotherapy JNJ-64041757 and Bristol-Myer Squibb’s PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), in NSCLC patients.

JNJ-64041757 is an antigen-presentation therapeutic, based on Live Attenuated Double-Deleted (LADD) Listeria monocytogenes strains engineered to induce an immune response against NSCLC tumours.

Janssen licensed JNJ-64041757 (previously referred to as ADU-214) and another compound, JNJ-64041809 (previously referred to as ADU-741), from Aduro Biotech, Inc., in 2014. Both are currently in Phase I clinical development: JNJ-64041757 in lung cancer and JNJ-64041809 in prostate cancer. OPDIVO is indicated for the treatment of patients with NSCLC with progression on or after platinum-based chemotherapy.

“Cancer immunotherapy is a key aspect of our emerging lung cancer portfolio,” said Matthew Lorenzi, PhD, Vice President, Lung Cancer, Janssen Research & Development. “This collaboration will help extend the clinical development of JNJ-64041757 while allowing us to gather data on the immune response triggered by the combination of these two innovative approaches.”

The study will be conducted by Janssen. Information, including anticipated study start, is expected to be posted on later this year. Additional details of the collaboration were not disclosed.